Premium
Cytokine Profiles in Acute Liver Failure Treated With Albumin Dialysis
Author(s) -
Ilonen Ilkka,
Koivusalo AnnaMaria,
Repo Heikki,
Höckerstedt Krister,
Isoniemi Helena
Publication year - 2008
Publication title -
artificial organs
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.684
H-Index - 76
eISSN - 1525-1594
pISSN - 0160-564X
DOI - 10.1111/j.1525-1594.2007.00454.x
Subject(s) - medicine , cytokine , liver transplantation , dialysis , albumin , gastroenterology , population , immunology , inflammation , interleukin , tumor necrosis factor alpha , transplantation , environmental health
Cytokines are released within the liver in response to hepatic injury, and acute liver failure (ALF) triggers systemic inflammation. Pro‐inflammatory (tumor necrosis factor‐alpha [TNF‐α] and interleukin‐8 [IL‐8]) and anti‐inflammatory (interleukin‐10 [IL‐10] and interleukin‐6 [IL‐6]) cytokines and the lymphocyte activation marker (interleukin‐2‐soluble receptor alpha chain [IL‐2sRα]) were monitored in 49 ALF patients considered for liver transplantation and treated with albumin dialysis (molecular adsorbent recirculating system [MARS]). Twenty‐six patients were categorized by clinical outcome as “good” (native liver recovered) and 23 as “poor” (patient bridged to liver transplantation or deceased). MARS did not clearly affect cytokine profiles during treatment; only IL‐10 levels decreased in the whole patient population and mostly in patients with the worst prognosis. In the good outcome group, IL‐8 and IL‐6 levels decreased during treatment; on the contrary, in poor outcome patients IL‐6 levels even increased. Initial IL‐2sRα levels were higher in poor outcome patients relative to the good outcome subset. Cytokine profiles seem to differ in ALF according to patient outcome. A deeper understanding of cytokine patterns during pathogenesis could reveal prognostic markers and aid the development of immunomodulating ALF therapies.